Therapeutic targeting of RNA splicing in cancer
EA Bonner, SC Lee - Genes, 2023 - mdpi.com
RNA splicing is a key regulatory step in the proper control of gene expression. It is a highly
dynamic process orchestrated by the spliceosome, a macro-molecular machinery that …
dynamic process orchestrated by the spliceosome, a macro-molecular machinery that …
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …
Alternative splicing and related RNA binding proteins in human health and disease
Y Tao, Q Zhang, H Wang, X Yang, H Mu - Signal Transduction and …, 2024 - nature.com
Alternative splicing (AS) serves as a pivotal mechanism in transcriptional regulation,
engendering transcript diversity, and modifications in protein structure and functionality …
engendering transcript diversity, and modifications in protein structure and functionality …
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
Mutations in splicing factor (SF) genes SRSF2, U2AF1, SF3B1, and ZRSR2 are now
considered adverse risk in the European LeukemiaNet 2022 acute myeloid leukemia (AML) …
considered adverse risk in the European LeukemiaNet 2022 acute myeloid leukemia (AML) …
RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
In lung adenocarcinoma (LUAD), loss-of-function mutations in the splicing factor RBM10
frequently co-occur with oncogenic EGFR mutations. A detailed understanding of the …
frequently co-occur with oncogenic EGFR mutations. A detailed understanding of the …
PPIA dictates NRF2 stability to promote lung cancer progression
W Lu, J Cui, W Wang, Q Hu, Y Xue, X Liu… - Nature …, 2024 - nature.com
Nuclear factor erythroid 2-related factor 2 (NRF2) hyperactivation has been established as
an oncogenic driver in a variety of human cancers, including non-small cell lung cancer …
an oncogenic driver in a variety of human cancers, including non-small cell lung cancer …
RNA-binding motif protein 10 inactivates c-Myc by partnering with ribosomal proteins uL18 and uL5
RNA-binding motif protein 10 (RBM10) is a frequently mutated tumor suppressor in lung
adenocarcinoma (LUAD). Yet, it remains unknown whether cancer-derived mutant RBM10 …
adenocarcinoma (LUAD). Yet, it remains unknown whether cancer-derived mutant RBM10 …
RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9
M Zhang, J Hyle, X Chen, Y Xin, Y Jin, J Zhang, X Yang… - Genome Biology, 2024 - Springer
Background The oncogenic protein HOXA9 plays a critical role in leukemia transformation
and maintenance, and its aberrant expression is a hallmark of most aggressive acute …
and maintenance, and its aberrant expression is a hallmark of most aggressive acute …
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in
patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML …
patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML …
Novel investigational agents and pathways that May influence the Future Management of Acute myeloid leukemia
N Premnath, YF Madanat - Cancers, 2023 - mdpi.com
Simple Summary Leukemia or blood cancer has been treated with chemotherapy since the
1970s. The treatment had undergone little change until the last decade when many new …
1970s. The treatment had undergone little change until the last decade when many new …